# Geroscience & senolytics

Selectively clearing senescent 'zombie' cells or suppressing their inflammatory secretome to treat age-related disease at its molecular root, rather than one downstream condition at a time.

Source: https://en.bioecon.ru/technology/geroscience-senolytics/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: European Innovation Partnership on Active and Healthy Ageing | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)]

Geroscience targets the shared molecular and cellular hallmarks of aging that underlie most chronic age-related diseases, rather than treating each disease separately. Its most clinically advanced arm is senolytics — small molecules or biologics that selectively clear senescent "zombie" cells, which stop dividing but resist apoptosis and instead secrete a toxic inflammatory cocktail (the senescence-associated secretory phenotype, or SASP) that drives chronic low-grade inflammation and drags neighboring healthy cells into senescence. Unity Biotechnology's lead senolytic, UBX1325, a Bcl-xL inhibitor delivered locally into the eye, has produced 36-week clinical results and a publication in NEJM Evidence supporting long-term vision improvement in diabetic macular edema. In a parallel clinical program, Mayo Clinic researchers ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring a reduction in senescent-cell markers in treated patients. Rubedo Life Sciences has reported positive preliminary Phase 1 results for RLS-1496, a topical GPX4-modulating senolytic for plaque psoriasis, atopic dermatitis and skin aging, identified through its AI-driven ALEMBIC platform. Altos Labs, launched around 2022 with roughly $3 billion in funding, is pursuing a parallel strategy — partial cellular reprogramming to reverse a cell's biological age without erasing its identity — rather than clearing senescent cells outright.

The key directions of geroscience and senolytics are:
1. **Senolytics:** small molecules or peptides that selectively trigger apoptosis in senescent cells by disabling their survival pathways (SCAP networks), such as Bcl-2/Bcl-xL inhibition or FOXO4-p53 disruption.
2. **Senomorphics:** compounds — such as mTOR inhibitors (rapamycin analogs) and metformin — that don't kill senescent cells but suppress their toxic SASP secretion.
3. **Cellular rejuvenation:** partial epigenetic reprogramming with Yamanaka factors to roll back a cell's biological age while preserving its cell-type identity.
4. **Senescence biomarking:** biomarker platforms (SA-β-gal activity, single-cell RNA-seq, SASP cytokine panels) used to identify senescent cells and measure how effectively a therapy clears them.

### Sectoral value chain

```
[Aging-Marker Identification] ──> [Senolytic Candidate Screening] ──> [Preclinical Testing (In Vivo)]
                  │                                 │                              │
        (SASP profiling, biomarkers)        (Compound libraries, HTS)    (Aged mouse models)
                                                                                    │
[Clinical Release (GMP)] <─── [Preclinical Synthesis & Purification (HPLC)] <──────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **1. Target identification** | Mapping senescent-cell survival (SCAP) networks and identifying unique surface antigens on senescent cells. | **In:** Senescent cell cultures, proteomic databases.<br>**Out:** Molecular target specification. |
| **2. HTS screening** | High-throughput screening of small-molecule or peptide libraries for selective induction of senescent-cell apoptosis. | **In:** Compound libraries, automated HTS stations.<br>**Out:** Senolytic candidate hits. |
| **3. Synthesis and purification** | Optimizing hit structure, synthesizing the drug substance, and purifying it by chromatography to high purity. | **In:** Chemical reagents/catalysts, HPLC.<br>**Out:** Purified senolytic active substance (>99%). |
| **4. Preclinical validation** | Testing senolytics in naturally aged mice: survival, cognitive and physical-function assays. | **In:** Aged mouse models, senolytic substance.<br>**Out:** Proven preclinical tissue rejuvenation and survival gains. |
| **5. Clinical strategy** | Designing trials against specific age-related indications (osteoarthritis, fibrosis, DME) rather than "aging" itself. | **In:** Clinical protocols, FDA/EMA requirements.<br>**Out:** Approved Phase I/II protocol for a specific indication. |
| **6. GMP formulation** | Manufacturing injectable (intra-articular/intravitreal) or oral dosage forms under GMP, fill-finish and packaging. | **In:** Purified senolytic substance, co-formulants.<br>**Out:** Finished therapeutic in GMP packaging. |

Cross-cutting technologies of the sector:
- **SA-β-gal detection:** the classic senescent-cell biomarker — enlarged lysosomes in senescent cells sharply raise beta-galactosidase activity at pH 6.0, letting researchers quantify how well a therapy clears zombie cells from tissue.
- **Bcl-2/Bcl-xL inhibition:** drugs (e.g., navitoclax, UBX1325) that block the anti-apoptotic Bcl-2-family proteins senescent cells rely on for survival, pushing the cell into programmed apoptosis.
- **FOXO4-DRI peptide design:** a synthetic peptide that disrupts the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger apoptosis while sparing healthy dividing cells.

---

## US

The US is the epicenter of the global longevity industry, combining a deep venture-capital ecosystem with pioneering academic geroscience centers.

### senolytic clinical trials, cellular reprogramming megaprojects, academic senolytic discovery
- **Unity Biotechnology:** its lead senolytic, UBX1325 (a Bcl-xL inhibitor), has produced 36-week clinical results and a NEJM Evidence publication supporting long-term vision improvement in diabetic macular edema and retinal disease.
- **Rubedo Life Sciences:** develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.
- **Altos Labs:** launched around 2022 with roughly $3 billion in funding, pursuing partial cellular reprogramming for cellular rejuvenation rather than senescent-cell clearance.
- **Mayo Clinic:** ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring reduced senescent-cell burden in treated patients.

---

## CN

China treats geroscience as a strategic response to rapid population aging and pension-system pressure, combining domestic senolytic discovery with dominance in a key longevity-supplement supply chain.

### aging research in Beijing, NAD+ precursor manufacturing, domestic senolytic compound discovery
- **Beijing research centers:** the Institute of Zoology (Chinese Academy of Sciences) and Peking University are China's leading aging-research centers, working on longevity-gene replacement approaches and natural senolytic compound discovery.
- **NAD+ precursor manufacturing scale:** China is the leading global producer and exporter of NAD+ coenzyme precursors such as nicotinamide mononucleotide (NMN), manufactured at large scale as a geroprotective supplement ingredient for export markets.
- **Policy support:** anti-aging research is incorporated into China's national technology development programs, driving parallel investment in epigenetic-clock biological-age diagnostics.

---

## EU

The EU concentrates on fundamental geroscience and peptide-based senolytic discovery, operating under an EMA framework that does not recognize aging itself as an indication.

### fundamental aging-pathway research, peptide senolytic design, EMA indication-specific regulation
- **Max Planck Institute for Biology of Ageing (Cologne):** a leading European academic hub studying molecular aging pathways (IIS, mTOR) in model organisms and coordinating geroprotector research across the EU.
- **Cleara Biotech (Netherlands):** founded in 2018, develops the FOXO4-DRI senolytic peptide, which disrupts the FOXO4-p53 interaction to selectively trigger apoptosis in senescent cells.
- **EMA regulatory posture:** EMA does not recognize biological aging as a standalone indication, so European senolytic developers must register their therapies against specific age-related diagnoses (e.g., idiopathic pulmonary fibrosis, osteoarthritis, sarcopenia) under existing disease codes.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Unity Biotechnology** | 🇺🇸 USA | *UBX1325* Bcl-xL inhibitor (retinal disease) | Local senolytic delivery via intravitreal injection | pilot |
| **Rubedo Life Sciences** | 🇺🇸 USA | *RLS-1496* (dermatology), ALEMBIC platform | AI-driven mapping of skin/lung senescent-cell heterogeneity | pilot |
| **Altos Labs** | 🇺🇸 USA | Cellular reprogramming platform | Yamanaka-factor partial reprogramming for cell rejuvenation | research |
| **Mayo Clinic** | 🇺🇸 USA | Dasatinib + Quercetin (D+Q) senolytic trials | Clinical validation of combination senolytic regimens | research |
| **Cleara Biotech** | 🇳🇱 Netherlands | *FOXO4-DRI* peptide | Peptidomimetic disruption of FOXO4-p53 complex | research |
| **Max Planck Institute for Biology of Ageing** | 🇩🇪 Germany | IIS/mTOR pathway research | Systemic analysis of molecular aging cascades | research |

---

## Tech stack and innovations

Modern geroprotector production and validation rests on the following technology stack:

1. **Solid-phase peptide synthesis (SPPS):**
   - Peptide senolytics like FOXO4-DRI are built stepwise on a solid resin using Fmoc-protected amino acids; substituting standard L-amino acids with mirror-image D-amino acids (retro-inverso peptides) makes them highly resistant to proteolytic degradation in blood.
2. **Single-cell RNA sequencing (scRNA-seq):**
   - Because senescent cells make up under roughly 1-5% of the total cell pool in aged tissue, bulk tissue sequencing can't detect their signal; scRNA-seq profiles the RNA expression of thousands of individual cells to map specific SCAP-network and SASP-cytokine markers.
3. **Ultra-high-performance liquid chromatography (UPLC-MS/MS):**
   - Used to quantify SASP biomarkers (IL-6, IL-1, MCP-1 and related inflammatory proteins) in patient serum before and after senolytic therapy, assessing systemic anti-inflammatory and rejuvenating effect.

---

## Value chains and production pipelines

### Industrial pipeline of GMP production for a peptide-type senolytic (FOXO4-DRI)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Solid-phase Fmoc       │ ───> │ 2. Cleavage from resin    │
│    synthesis (D-amino     │      │    with acid (TFA)         │
│    acids)                 │      │                            │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Membrane dialysis &    │ <─── │ 3. RP-HPLC chromatography │
│    desalting (TFF)        │      │    (substance purity)      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Buffer formulation &   │ ───> │ 6. Sterile filtration &   │
│    SA-gal potency assay   │      │    aseptic fill-finish     │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Solid-phase peptide synthesis (SPPS)
A polymeric resin support (e.g., Rink amide resin) is loaded into an automated peptide synthesizer to build the FOXO4-DRI retro-inverso peptide from D-amino acid isomers, cycling through Fmoc deprotection, activation and coupling for each residue.

#### Stage 2: Cleavage from the polymeric support
Once the sequence is complete, the resin is washed and treated with a trifluoroacetic acid (TFA)/water/triisopropylsilane mixture, which cleaves the peptide from the resin and removes side-chain protecting groups; the crude peptide is precipitated in cold ether and dried.

#### Stage 3: Preparative RP-HPLC purification
The crude peptide is dissolved and loaded onto a C18 reverse-phase HPLC column, purified by an acetonitrile gradient, and collected at target purity (typically at least 98%) by UV detection.

#### Stage 4: Desalting and acetate-salt conversion
The eluate is processed by tangential-flow filtration (TFF) with a low-molecular-weight-cutoff membrane, exchanging residual TFA ions for physiological acetate ions via repeated diafiltration.

#### Stage 5: Formulation and potency testing
The purified peptide acetate is dissolved in sterile phosphate-buffered saline; identity and purity are confirmed by high-resolution mass spectrometry, and an in-vitro potency assay confirms selective apoptosis of senescent (SA-β-gal-positive) fibroblasts without harming healthy dividing controls.

#### Stage 6: Sterile filtration, fill and lyophilization
The formulated solution is sterile-filtered, filled into vials in a GMP Class A aseptic zone, lyophilized, sealed, labeled and stored under refrigeration ahead of clinical use.